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http:WHAT THIS PAPER ADDS
An evidence-based guideline on optimal urokinase and heparin doses for thrombolysis of thromboembolic
peripheral arterial occlusions has not been produced to date. High-dose urokinase protocols are commonly
used, but are accompanied by high rates of major and minor bleeding complications. This study shows that low-
dose thrombolysis appears to be as effective as high-dose thrombolysis. In addition, low-dose thrombolysis
results in a substantially lower risk of major bleeding complications.Objective: To evaluate the efﬁcacy and bleeding complications associated with a low-dose thrombolysis protocol
for thromboembolic lower extremity arterial occlusions.
Design: A retrospective cohort study.
Materials and methods: A retrospective analysis was performed using data from all consecutive patients who
underwent catheter-directed, intra-arterial thrombolysis for thromboembolic lower extremity arterial occlusions
between January 2004 and May 2013. All patients were treated on a standard surgical ward. Endpoints were
incidence of bleeding complications, duration of thrombolysis, angiographic patency rate, 30-day mortality rate,
and amputation-free rate at 6 months.
Results: Of the 171 cases analyzed, 129 cases underwent low-dose thrombolysis and 42 underwent high-dose
thrombolysis. No major bleeding complications occurred in the low-dose group versus 5% in the high-dose group
(p ¼ .01). The median duration of thrombolysis was 67 hours (4e304 hours) in the low-dose and 49 hours (2e
171 hours) in the high-dose group (p ¼ .027). Angiographic patency was restored in 67% of the cases in the low-
dose group versus 79% of the high-dose group (p ¼ .17). The 30-day mortality rates were 1% in the low-dose
versus 5% in the high-dose group (p ¼ .09). However, this higher mortality rate was not related to bleeding
complications. Major amputation-free rates at 6 months were 81% in the low-dose group and 88% in the high-
dose group (p ¼ .22).
Conclusions: Based on this data series, low-dose thrombolysis for thromboembolic lower extremity arterial
occlusions is as effective as high-dose thrombolysis; however, the risk of major bleeding complications is
substantially lower when using low-dose thrombolysis.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Prior to the 1990s, the standard treatment for acute leg
ischemia was surgical thromboembolectomy. The publica-
tion of several prospective randomized trials in the 1990s
showed that thrombolysis might represent an effective
alternative to primary surgical intervention.1,2 Since these
landmark trials, a consensus has been reached thatrresponding author. A.W.J. Hoksbergen, VU University Medical Cen-
. Box 7057, 1007 MB Amsterdam, The Netherlands.
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//dx.doi.org/10.1016/j.ejvs.2014.06.042thrombolysis can be viewed as a ﬁrst-line treatment for
many cases of thromboembolic lower extremity arterial
occlusion.3e5 Although a range of ﬁbrinolytic agents and a
variety of dose protocols have been used for thrombolysis,6
most studies have reported results of urokinase (UK) at
doses of more than 100,000 IU/hr, together with varying
doses of heparin. These studies reported major bleeding
rates ranging from 6% to 13%, including 2% intracranial
bleeding, and minor bleeding complications in 5% to 17% of
patients.1,2,7,8 Overall, success rates for high-dose throm-
bolysis are reported to be around 70% (Table 1).
Before 2011, a low-dose thrombolysis protocol consisting
of a 500,000 IU UK intra-arterial bolus, followed by
continuous infusion of 50,000 IU UK/hr and 4,800 IU of
Table 1. High-dose urokinase thrombolysis protocols.
Author N Urokinase dose Heparin dose Success
rate
Major
bleeding
Intracranial
bleeding
Minor
bleeding
Amputation-free
rate
Mortality
Cragg 19918 35 250,000 IU bolus Intravenous heparin:
2e3  APTT
77% 6% None 17% 92% at 30 d 2% at 30 d
250,000 IU/hr
for 4 hr
125,000 IU/hr
up to 24 hr
STILE 19942 66 250,000 IU bolus 5,000 IU bolus
þ 1,000
IU/hr intravenous
heparin:
1.5e2  APTT
þ intra-arterial
heparin following
institutional
protocol
75% 6% 2% 5% 87% at 6 mo 4% at 30 d
8% at 6 mo
240,000 IU/hr
for 4 hr
120,000 IU/hr
up to 36 hr
Ouriel 19981 272 240,000 IU/hr
for 2 hr
Intravenous heparin:
1.5e2  APTT
(>only ﬁrst 67
patients,
hereafter:
subtherapeutic)
68% 13% 2% 5% 72% at 6 mo 16% at 6 mo
120,000 IU/hr
up to 48 hr
Duda 20017 70 25,000 IU bolus
per 10 cm
thrombus
50 IU/kg bolus
þ 7 IU/kg/hr
intravenous
heparin
70% 6% None 13% 88% at 6 mo 8% at 6 mo
240,000 IU/hr
for 2 hr
120,000 IU/hr
for 2 hr
240,000 IU/hr
for 2 hr
d ¼ day(s); hr ¼ hour(s); mo ¼ month(s); N ¼ number of cases.
552 H.P. Ebben et al.heparin per 24 hours was routinely used in our university
hospital. In mid-2011 this protocol was replaced by a high-
dose protocol (100,000 IU UK/hr and 9,600 heparin/24 hr).
Two factors triggered this decision: a nationwide survey on
thrombolysis practice revealed that most Dutch hospitals
use high-dose protocols, and the successful use of a high-
dose protocol during a clinical trial to evaluate
ultrasound-accelerated thrombolysis compared with stan-
dard thrombolysis. However, the safety and effectiveness of
high-dose thrombolysis was called into question at the VU
University Medical Center following two incidents of major
bleeding complications in rapid succession. This was the
rationale underlying the decision to retrospectively evaluate
thrombolysis success rates and bleeding complications of
both the low- and high-dose thrombolysis protocols.MATERIALS AND METHODS
This retrospective analysis included data from all consecu-
tive patients who underwent thrombolysis for thrombo-
embolic occlusions of native arteries or bypass grafts distalto the aortic bifurcation in the period January 2004eMay
2013. Approval was granted from the institutional ethics
review board. The results for patients treated with low- and
high-dose protocols were analyzed separately.
Clinical and outpatient records, radiological reports, sur-
geons’ and nurses’ reports were all reviewed. Patients were
excluded on the basis of a thromboembolic occlusion
directly caused by an endovascular intervention and when
treated with an EKOS EndoWave infusion catheter system,9
as patency rates, lysis duration, doses of urokinase and
heparin, and therefore risk of hemorrhagic complications,
are probably inﬂuenced by this new thrombolysis tech-
nique. Recommendations in the literature were followed, so
occlusions in patients with symptoms of less than 14 days
duration were deﬁned as acute, and those with symptoms
of 14 days or more as non-acute.2
At the VU University Medical Center, thrombolysis is only
performed as a primary treatment for suspected thrombo-
embolic peripheral arterial occlusions in patients with viable
extremities, that is not in immediately threatened limbs
(Rutherford IIb/III) or in patients without evident pre-
276 cases in 199 patients with thromboembolic peripheral arterial occlusions 
171 cases in 121 patients  
59 treated with an EKOS catheter
44 occlusions as a result of endovascular arterial interventions
2 miscellaneous reasons 
129 cases treated with 
low-dose thrombolysis 
42 cases treated with 
high-dose thrombolysis 
87 (67%) angiographic 
patency restored 
33 (79%) angiographic 
patency restored* 
Figure 1. Ex- and included cases and outcome; values presented are cases. * Angiographic patency was restored in 87 cases (67%) in the
low-dose versus 33 cases (79%) in the high-dose group (p ¼ .17).
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acute ischemia suggesting an embolic cause. Contraindica-
tions for thrombolysis were active internal bleeding, recent
(<10 days) surgery or trauma, recent (<1 month) peptic
ulcer or gastrointestinal bleeding, esophageal varices,
recent (<3 months) intracranial bleeding, intracranial tu-
mor, aneurysm or malformation, recent (<1 month) car-
diopulmonary resuscitation, thrombocytopenia
(<150  109/L), and coagulation disorders.
The standard thrombolysis protocol consisted of a
500,000 IU UK (Medac GmbH, Hamburg, Germany) lacing
dose, followed by a continuous infusion of 50,000 IU/h UK.
After ipsilateral antegrade puncture or contralateral retro-
grade puncture under ultrasound guidance, an intra-arterial
thrombolysis catheter (Royal Flush High-Flow, Cook Medi-
cal, Amsterdam, the Netherlands) was advanced via a guide
wire and placed into the proximal end of the thrombus or
as close as possible. A continuous dose of 4,800 IU/24 hr of
heparin was infused through the side-port of the sheath to
prevent peri-catheter clotting. After successful thrombolysis
of the target artery, patients with residual hemodynamically
signiﬁcant stenoses in the in- or outﬂow tract underwent
PTA or surgical revision in the absence of endovascular
treatment options.
In the second half of 2011, the low-dose protocol was
changed to a high-dose protocol for the reasons mentioned
earlier. This protocol consisted of a 500,000 IU UK lacing
dose, followed by continuous infusion of 100,000 IU/hr UK
together with a continuous heparin dose of 9,600 IU/24 hr,
a doubling of the continuous doses of urokinase and hep-
arin. Decisions regarding follow-up angiograms, continua-
tion of therapy, and additional procedures were made by a
dedicated team of vascular surgeons and interventional
radiologists. The number of follow-up angiograms per 24hours depended on the severity of ischemia and the pro-
gression of thrombolysis. Patients were routinely treated on
a standard surgical ward. All nurses and clinical residents
involved in treatment underwent extensive training and had
both paper and electronic access to the thrombolysis pro-
tocol at all times.
Hemoglobin (Hb), thrombocytes, Activated Partial
Thromboplastin Time (APTT, normal range 25e40 seconds),
Prothrombin Time measured as International Normalized
Ratio (INR, normal range 0.80e1.20), and ﬁbrinogen levels
(normal range 200e400 mg/dL) were monitored at
admission and daily. In cases with a ﬁbrinogen level below
100 mg/dL, the UK dose was halved and the ﬁbrinogen
level was checked after 3 hours. If the ﬁbrinogen level
dropped below 50 mg/dL, UK infusion was stopped and the
catheter perfused with NaCl 0.9%. After a period of 3
hours, the ﬁbrinogen level was checked again and therapy
was continued if the ﬁbrinogen level had recovered to
greater than 100 mg/dL. During therapy, aspirin was
continued but no coumarines, low molecular weight hep-
arins, or intravenous heparins were administered. Patients
on coumarines or warfarin with INR greater than 3.5 at
admission received vitamin K, and thrombolysis was initi-
ated only when INR was less than 2.5. After successful
thrombolysis, patients were routinely heparinized and oral
anticoagulant treatment was started with a target INR
range of 2.5e3.5.
Thrombolysiswas considered successfulwhenangiographic
patency was restored, that is restoration of luminal continuity
without signiﬁcant residual thrombus. Intra- and retroperito-
neal bleeding, intracranial bleeding, and all bleeding compli-
cations requiring blood transfusion or invasive procedures
were considered potentially life-threatening, and therefore
categorized as major bleeding complications. Minor bleeding
Table 2. Baseline characteristics of patients.
Low-dose
group
(n ¼ 129)
High-dose
group
(n ¼ 42)
p
Age (in years, mean  SD) 64 (12) 64 (10) .94
Sex (% male) 57 67 .29
Vascular history (%) 77 86 .38
Cardiac history (%) 35 31 .75
Current tobacco use (%) 57 61 .70
Hypertension (%) 77 83 .37
Hyperlipidemia (%) 81 86 .47
Diabetes (%) 23 36 .11
Tissue necrosis at
hospital admission (%)
14 10 .12
Duration of symptoms
(d, mean  SD)
8 (11.8) 8 (11.9) .29
d ¼ days.
Table 3. Occlusion characteristics.
Low-dose
group
(n ¼ 129)
n (%)
High-dose
group
(n ¼ 42)
n (%)
p
Acute 102 (79) 31 (74) .48
Non-acute 27 (21) 11 (26)
Native artery 69 (53) 17 (40) .14
Bypass graft 60 (47) 25 (60)
Venous graft 14 (23) 5 (20) .29
Prosthetic graft 45 (75) 19 (76)
Combined graft 1 (2) 1 (4)
Location occluded
segment
Aorto-iliac 24 (19) 13 (31) .18
Femoral 73 (56) 23 (55)
Popliteal 24 (19) 3 (7)
Crural 8 (6) 3 (7)
Acute is deﬁned as occlusion with symptoms for less than 14 days.
Non-acute is deﬁned as occlusion with symptoms for 14 days or
more. N ¼ Number of cases.
554 H.P. Ebben et al.complications were deﬁned as bleeding at any other site not
requiring blood transfusion or invasive treatment.
The data were analyzed using SPSS (IBM Statistics v20,
Chicago, IL, USA). A ManneWhitney-U test or an unpairedTable 4. Treatment characteristics.
Low-
(n ¼
Treatment duration (in hr, median þ range) 67 (4
Total UK dose (in million IU, mean  SD) 4.7 (
Angiography frequency (per 24 hr,
median þ range)
1.0 (
APTT (in s, mean  SD) 59 (
INR (ratio, mean  SD) 1.5 (
Fibrinogen (in mg/dL, mean  SD) 264
Technical success rate (%) 99
Patency rate (%) 67
Major bleeding complications (%) 0
Minor bleeding complications (%) 5
30-d mortality rate (%) 1
6 mo amputation-free rate (%) 81
APTT ¼ Activated Partial Thromboplastin Time; d ¼ days; hr ¼ hoursStudent t test was used to compare continuous variables
with (non)parametric distributions. A chi-square test was
used to compare proportions between groups. A p value
less than .05 was considered statistically signiﬁcant.
RESULTS
During the inclusion period, thrombolysis was performed
for 276 cases of lower extremity arterial occlusion in 199
patients. A total of 171 cases were included, 129 cases in
103 patients treated with low-dose thrombolysis and 42
cases in 29 patients treated with high-dose thrombolysis.
Reasons for exclusion and patient outcomes are described
in Fig. 1. Characteristics of included patients and occlusions
are summarized in Tables 2 and 3, respectively. Baseline and
occlusion characteristics were not signiﬁcantly different
between groups.Treatment characteristics and results
Treatment characteristics of both groups are summarized in
Table 4. The median duration of thrombolysis was 67 hours
(range 4e304 hours) in the low-dose versus 49 hours (2e
171 hours) in the high-dose group (p ¼ .027), and the
median frequency of follow-up angiograms was 1.0 (0.3e
2.3) versus 1.5 (1.1e4.0) per 24 hours (p < .001). Angio-
graphic patency was restored in 87 cases (67%) in the low-
dose versus 33 cases (79%) in the high-dose group
(p ¼ .17). For the low-dose group, success rates increased in
the second half of the inclusion period: in the period 2004e
2008, patency was restored in 57% of the cases versus 77%
in the period 2009e2013 (p ¼ .02).
The median length of admission for all patients was 9
days (2e147 days). Patients successfully treated with
thrombolysis had a signiﬁcantly shorter in-hospital stay,
independent of dose regimen, than patients in whom
thrombolysis failed; 8 (2e82 days) versus 13 days (2e147
days), respectively (p ¼ .001).
Success rates of thrombolysis for all cases were higher
(although still non-signiﬁcant) for acute compared with
non-acute occlusions; 73% versus 61% respectivelydose group
129)
High-dose group
(n ¼ 42)
p
e304) 49 (2e171) .03
3.1) 6.1 (3.8) .02
0.3e2.3) 1.5 (1.1e4.0) <.001
30) 65 s (52) .29
0.4) 1.7 (0.6) .04
(114) 204 (65) .002
100 .75
79 .17
5 .01
7 .39
5 .15
88 .32
; INR ¼ International Normalized Ratio; mo ¼ months.
77%
75%
87%
68% 72%70%
88%
67%
81%79%
88%
Success rates Amputation-free rates
at 6 months
0%
6%
17%
2%
6%
5%
2%
13%
5%
0%
6%
13%
0% 0%
5%
2%
5%
7%
Intracranial bleedings Major bleedings Minor bleedings
A
B
NR
Figure 2. Comparison of results with literature. (A) Success rates, amputation-free rates at 6 months. (B) Bleeding complications. NR ¼ not
reported.
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patients successfully treated with thrombolysis compared
with non-successfully treated patients was signiﬁcantly
shorter at 3 days (0e67 days) versus 7 days (0e60 days),
respectively (p ¼ .006). The success rates of thrombolysis
for occluded native arteries and bypass occlusions did not
differ (70% vs. 71%), and thrombolysis of prosthetic by-
passes was signiﬁcantly more successful than thrombolysis
of venous bypasses at 77% versus 53%, respectively
(p ¼ .04). All of the above outcome parameters wereindependent of dose regimen. Univariate analysis showed
that a variety of factors including history of vascular in-
terventions, cardiac history, diabetes, smoking, hyperlipid-
emia, and hypertension did not signiﬁcantly inﬂuence
thrombolytic success.
Complications
Although no major bleeds occurred in the low-dose group,
minor bleeding was noted in six cases (5%), including
bleeding at the puncture site in ﬁve cases and hematuria in
556 H.P. Ebben et al.a single case. Two of these six cases developed a groin
hematoma, which led to the premature cessation of
thrombolytic therapy. Other complications included
delirium (2 cases), compartment syndrome of the leg (2),
pseudoaneurysm formation (1), ischemic stroke (1), and
temporary kidney failure (1).
Two cases with major bleeding complications occurred in
the high-dose group, including one case of intracranial
bleeding and one of intra-abdominal bleeding. These cases
resulted in a major bleeding complication rate of 5% in the
high-dose group versus 0% in the low-dose group (p ¼ .01).
The high-dose group also included three minor bleeds (7%),
with bleeding at the puncture site, versus six cases (5%) in
the low-dose group (p ¼ .39). Total UK dose was not
signiﬁcantly different between patients who developed a
major hemorrhage and patients who did not, 5.5 million IU
(3.7e7.3) versus 4.5 million IU (0.7e17.6) (p ¼ .61).
Pseudoaneurysm formation of the femoral artery
occurred in one patient in the high-dose group.Follow-up of low-dose cases
Of the 87 cases successfully treated with low-dose throm-
bolysis, 42 (48%) underwent an additional percutaneous
intervention and eight (9%) underwent an additional sur-
gical intervention (revision of bypass anastomosis, lumbar
sympathectomy, toe amputation, or below knee amputa-
tion) within the period of admission. The causes of unre-
stored patency in the remaining 42 cases were no or
marginal lysis in 33, initial lysis followed by direct re-
occlusion in four, cessation of therapy because of compli-
cations in three (catheter luxation because of a fall out of
bed in one case, groin hematoma in two cases), technical
failure (not possible to advance catheter) in one, and non-
compliance in one case. In 21 cases without restored
patency, surgical revascularization was attempted (throm-
boembolectomy in 11 and bypass surgery in 10 cases; ﬁve
of these cases underwent additional major amputation
within 30 days) and direct major amputation was performed
in 12 cases. One patient refused further treatment and in
the remaining eight cases, despite lack of restoration of
patency in the target artery, thrombolysis resulted in clinical
improvement and the patients could return home without
any additional intervention.Follow-up of high-dose cases
Of the 33 cases successfully treated with high-dose
thrombolysis, 11 (33%) underwent an additional percuta-
neous intervention and three (9%) underwent an additional
surgical intervention (revision of bypass anastomosis, toe
amputation) within the period of admission. In the high-
dose group, nine cases showed unrestored patency with
causes including no or only marginal lysis in six, cessation of
the procedure because of complications in two, and initial
lysis followed by direct re-occlusion in one case. Major
amputation followed for four of these nine cases, and twocases underwent thromboembolectomy. Although patency
of the target artery was not restored in two cases, throm-
bolysis resulted in clinical improvement and the patients
could return home without any additional intervention.
Finally, one patient underwent a second course of throm-
bolysis treatment.Follow-up comparisons
30-day mortality rates were not signiﬁcantly different be-
tween low- and high-dose groups, 1% versus 5% (p ¼ .09).
Amputation-free- and re-intervention-free rates at 6
months for the low- versus high-dose groups were 81%
versus 88% (p ¼ .22) and 82% versus 71% (p ¼ .14),
respectively, on an intention to treat basis In the low-dose
group, the death of one patient was caused by (pre-existing)
heart failure, and one patient in the high-dose group died
from (pre-existing) heart failure and a concomitant refusal
of further therapy. An additional patient died 2 weeks after
hospital discharge in good condition because of a traumatic
subdural hematoma complicated by renal failure.Laboratory values
Although the mean APTT values over the whole treatment
period did not differ between groups (low vs. high) at 59
seconds (30 s) versus 65 seconds (52 s) (p ¼ .29), the
mean INR in the high-dose group was signiﬁcantly higher at
1.5 (0.4) versus 1.7 (0.6) (p ¼ .04). Mean ﬁbrinogen
levels were also signiﬁcantly higher in the low-dose group
compared with the high-dose group, 260 (110) versus 200
(60) mg/dL, respectively (p ¼ .002). All cases with major
and minor bleeding complications showed ﬁbrinogen levels
greater than 100 mg/dL, and APTT and INR were within
normal ranges on the day of the bleeding complication.
The APTT exceeded 60 seconds at least once within the
treatment period in 67% of the cases in the low-dose group
versus 55% in the high-dose group, indicating therapeutic
treatment ranges despite the low-dose intra-arterial heparin
administration. Furthermore, 51%of the cases in the low-dose
group versus 48% in the high-dose group showed an INR
greater than 2.0 at least once within the treatment period,
indicating that INR levels were also within therapeutic ranges.
Fibrinogen levels dropped below 100 mg/dL in 12% of the
cases in the low-dose group (13 of 16 within the ﬁrst 24 hours
of therapy) and in 21% of the cases (4 of 9 within the ﬁrst 24
hours of therapy) in the high-dose group. Two per cent of the
cases in the low-dose group showed ﬁbrinogen levels of less
than or equal to 50 mg/dL versus 7% in the high-dose group.
DISCUSSION
An evidence-based guideline on optimal urokinase and hep-
arin doses for the thrombolysis of thromboembolic peripheral
arterial occlusions has not been produced to date. High-dose
urokinase protocols are frequently used but are accompanied
by high rates of major (6e13%) and minor (up to 17%)
bleeding complications.1,2,7,8 Although the success rate of
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with the success rates of high-dose studies published in the
literature (Fig. 2A), the most signiﬁcant ﬁnding of this study
was that comparable angiographic patency rates were ach-
ieved without major bleeding complications (Fig. 2B). Inter-
estingly, results using low-dose thrombolysis also improved
over time, from 57%patency in the period 2004e2008 to 77%
in the period 2009e2013 (p ¼ .02), while baseline and oc-
clusion characteristics remained stable. This improvement
may be attributable to improved radiological skills. Overall,
thrombolysis in prosthetic grafts was more successful than in
venous grafts (77% vs. 53% respectively, p ¼ .04), a ﬁnding
also reported by several other studies.10,11 This again raises
the question of whether initial thrombolysis is the best
therapy for occluded vein grafts.
Similar rates of major bleeding complications were
observed in the high-dose thrombolysis group when
compared with the literature, once again emphasizing the
increased bleeding risk associated with treatment with
higher doses of ﬁbrinolytics and heparin. The overall 30-day
mortality rate in this study was 2%, comparable with the 2%
mortality rate reported by Cragg et al., but lower than the
4% reported for the STILE trial.2,8 The TOPAS trial did not
report 30-day mortality rates.
The low rate of bleeding complications in the low-dose
group can be explained by the low-dose infusion of uroki-
nase, as well as by the low dose of the concomitantly
administered heparin. Which of these factors contributes
most to the favorable outcome cannot be determined from
the present study. Despite the intended subtherapeutic
intra-arterial administration of heparin to prevent peri-
catheter clotting, APTT levels were within therapeutic
ranges in the majority of patients at least once within the
treatment period. This may be because of the potential
synergistic effects of urokinase and heparin.12,13 The
concomitant use of unfractionated intravenous heparin
during thrombolysis remains controversial.14,15 In the
TOPAS trial, the use of intravenous heparin (intended APTT
1.5e2 times the control value) was aborted after treatment
of 62 patients, when the safety monitoring committee
identiﬁed an unacceptably high rate (4.8%) of intracranial
bleeding.1 The initial requirement for therapeutic doses of
systemic heparin was abandoned and replaced by sub-
therapeutic amounts of heparin, administered through the
arterial sheath. This resulted in a drop in the rate of intra-
cranial bleeding to 0.5%, suggesting a signiﬁcant link be-
tween the co-administration of intravenous therapeutic
doses of heparin and the risk of major bleeding. Another
drawback of heparin use is the possible induction of
heparin-induced thrombocytopenia thrombosis (HITT),
which is rare but is associated with a high morbidity and
mortality.16 To the authors’ knowledge, a randomized trial
of thrombolysis with and without concomitant heparin
administration has not been performed. The necessity for
and safety of concomitant heparin infusion, whether
intended as therapeutic or as subtherapeutic to prevent
peri-catheter clotting and potential thrombus propagation,
is questionable and should be further investigated.The clinical use of laboratory tests during thrombolysis is
controversial.17 Although ﬁbrinogen depletion was identi-
ﬁed in the STILE trial as a risk factor for bleeding compli-
cations during thrombolysis with urokinase,2 a lack of other
randomized controlled trials in the literature means that
this is still an isolated ﬁnding. In this study, ﬁbrinogen levels
of patients with bleeding complications were all >100 mg/
dL on the day of occurrence.
In the present study and in other studies, angiographic
patency, that is restoration of luminal continuity, was used
to deﬁne success of thrombolysis.1,2,7,8,18 However, despite
restoration of luminal continuity of the target artery, poor
distal run-off might result in early reocclusion and thus
hamper clinical improvement and indicate failed treatment.
The opposite e clinical improvement without successful
lysis of the target artery e might also occur and could be
explained by lysis of a thrombus in important collateral or
outﬂow arteries, leading to relief of ischemia. In 5% of the
cases, angiographic blood ﬂow was restored but no clinical
improvement was found, necessitating additional surgical
therapy (bypass-revision, thromboembolectomy, or major
amputation). By contrast, in 4% of the cases clinical
improvement was seen without restoration of luminal
patency in the target artery.
In this study, thrombolysis was continued as long as
progression of lysis was observed on follow-up angiograms,
without clinical deterioration demanding a change of ther-
apy. The median duration of therapy in the low-dose group
was nearly 3 days. Other studies have described protocols
that stop thrombolytic treatment at deﬁned points such as
7, 24, 36, or 48 hours,1,2,7,8 although reasons for this strict
discontinuation of thrombolysis at predeﬁned time points
were not reported. The relatively long duration of therapy
in this study might be partly explained by the lower dose of
urokinase. Despite the longer therapy duration in the low-
dose group, which might also inﬂuence limb salvage, the
6-month amputation-free rate of 81% is comparable with
that reported in the literature1,2,7,8 (Fig. 2A). The frequency
of follow-up angiograms might also inﬂuence therapy
duration, with a higher frequency potentially resulting in
earlier cessation of therapy. In the high-dose group, more
angiograms were performed because faster reperfusion was
anticipated, preventing unnecessary overnight continuation
of thrombolysis. Duration of ischemia is another factor that
might inﬂuence success of thrombolysis and risk of major
amputation. The STILE investigators found a non-signiﬁcant
trend towards an advantage for surgery compared with
thrombolysis in the combined death and amputation
outcome (9.9% vs. 17.8%; p ¼ .08) in the group with
symptoms lasting more than 14 days. However, in the group
with symptoms of less than 14 days duration thrombolysis
performed signiﬁcantly better than surgery, 15.3% versus
37.5% respectively (p ¼ .01).2 This resulted in guidelines
advising thrombolysis only for recent occlusive events,
deﬁned as symptoms lasting for a maximum of 14 days.17
The patency rates of thrombolysis in the present study
were (non-signiﬁcantly) higher for acute compared with
non-acute occlusions, 73% versus 61%, respectively
558 H.P. Ebben et al.(p ¼ .14). In addition, patients successfully treated with
thrombolysis compared with non-successfully treated pa-
tients had a shorter history of symptoms, 3 versus 7 days,
respectively (p ¼ .006). In the present data series, throm-
bolysis was successful in ﬁve out of eight cases with oc-
clusions with a duration of 1 month or longer. Patients with
long-lasting occlusions who are unﬁt to undergo surgical
intervention might therefore be considered candidates for
thrombolysis. Additionally, as more than half of patients
receiving thrombolysis in the STILE trial underwent reduced
surgical procedures,2 thrombolysis might reduce the
magnitude of additional interventions.
Limitations
Although this was a retrospective study, the authors
consider this study relevant, as there is a lack of available
evidence on optimal thrombolytic dosage for peripheral
arterial occlusions and major hemorrhage still remains a
signiﬁcant problem of this minimal invasive technique.4
Potential bias could have been introduced by the com-
parison of non-contemporaneous groups. However, the
authors do not think that this could have inﬂuenced the
hemorrhage rate.
Finally, because of the absence of major bleeding com-
plications, performing low-dose thrombolysis on a general
surgical ward appears to be safe.With an increasing number
of patients undergoing thrombolysis, this option could
reduce the logistic burden on special care units and might
also lower the costs of therapy.
Conclusion
Based on the present data series, low-dose thrombolysis for
thromboembolic lower extremity arterial occlusions ap-
pears to be as effective as high-dose thrombolysis. In
addition, low-dose thrombolysis results in a substantially
lower risk of major bleeding complications.
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